Related references
Note: Only part of the references are listed.Adipose Tissue Macrophage Phenotypes and Characteristics: The Key to Insulin Resistance in Obesity and Metabolic Disorders
Yinhua Ni et al.
OBESITY (2020)
Myeloid-specific Asxl2 deletion limits diet-induced obesity by regulating energy expenditure
Wei Zou et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
MicroRNA-99a mimics inhibit M1 macrophage phenotype and adipose tissue inflammation by targeting TNFα
Anant Jaiswal et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2019)
Fibroblast activation protein restrains adipogenic differentiation and regulates matrix-mediated mTOR signaling
Rachel Blomberg et al.
MATRIX BIOLOGY (2019)
Fibroblast activation protein is dispensable for control of glucose homeostasis and body weight in mice
Brandon L. Panaro et al.
MOLECULAR METABOLISM (2019)
Dipeptidyl peptidase IV (DPP-IV) inhibition prevents fibrosis in adipose tissue of obese mice
Ana Patricia Marques et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2018)
Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics
Ellen Pure et al.
ONCOGENE (2018)
Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes
Carolyn F. Deacon
PEPTIDES (2018)
Fibroblast growth factor 21 increases insulin sensitivity through specific expansion of subcutaneous fat
Huating Li et al.
NATURE COMMUNICATIONS (2018)
Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance
Devram S. Ghorpade et al.
NATURE (2018)
Fibroblast Growth Factor 21-Metabolic Role in Mice and Men
Harald Staiger et al.
ENDOCRINE REVIEWS (2017)
Role of innate and adaptive immunity in obesity-associated metabolic disease
Tracey McLaughlin et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Inflammasome-driven catecholamine catabolism in macrophages blunts lipolysis during ageing
Christina D. Camell et al.
NATURE (2017)
Sympathetic neuron-associated macrophages contribute to obesity by importing and metabolizing norepinephrine
Roksana M. Pirzgalska et al.
NATURE MEDICINE (2017)
Adapting to obesity with adipose tissue inflammation
Shannon M. Reilly et al.
NATURE REVIEWS ENDOCRINOLOGY (2017)
Obesity
Pedro Gonzalez-Muniesa et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
The FGF21-CCL11 Axis Mediates Beiging of White Adipose Tissues by Coupling Sympathetic Nervous System to Type 2 Immunity
Zhe Huang et al.
CELL METABOLISM (2017)
Circulating FGF21 proteolytic processing mediated by fibroblast activation protein
Eugene Y. Zhen et al.
BIOCHEMICAL JOURNAL (2016)
Fibroblast Activation Protein Cleaves and Inactivates Fibroblast Growth Factor 21
Diana Ronai Dunshee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Fibroblast activation protein (FAP) as a novel metabolic target
Miguel Angel Sanchez-Garrido et al.
MOLECULAR METABOLISM (2016)
Human FGF-21 Is a Substrate of Fibroblast Activation Protein
Andrew L. Coppage et al.
PLOS ONE (2016)
Macrophages, Immunity, and Metabolic Disease
Joanne C. McNelis et al.
IMMUNITY (2014)
A decade of progress in adipose tissue macrophage biology
Andrea A. Hill et al.
IMMUNOLOGICAL REVIEWS (2014)
A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity
Daniel A. Bachovchin et al.
NATURE CHEMICAL BIOLOGY (2014)
Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia
Edward W. Roberts et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Val-BoroPro Accelerates T Cell Priming via Modulation of Dendritic Cell Trafficking Resulting in Complete Regression of Established Murine Tumors
Meghaan P. Walsh et al.
PLOS ONE (2013)
Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome
Daniela Lamers et al.
DIABETES (2011)
Pro-Soft Val-boroPro: A Strategy for Enhancing in Vivo Performance of Boronic Acid Inhibitors of Serine Proteases
Sarah E. Poplawski et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma
Robert M. Eager et al.
BMC CANCER (2009)
Phase II Trial of Talabostat and Docetaxel in Advanced Non-small Cell Lung Cancer
R. M. Eager et al.
CLINICAL ONCOLOGY (2009)
Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice
Angelica M. Santos et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice
I. Murano et al.
JOURNAL OF LIPID RESEARCH (2008)
Phase II trial of single agent Val-boroPro (Talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer
Kalyani Narra et al.
CANCER BIOLOGY & THERAPY (2007)
Talabostat
Charles Casey Cunningham
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
Obesity induces a phenotypic switch in adipose tissue macrophage polarization
Carey N. Lumeng et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Fibroblast activation protein-α and dipeptidyl peptidase IV (CD26):: Cell-surface proteases that activate cell signaling and are potential targets for cancer therapy
T Kelly
DRUG RESISTANCE UPDATES (2005)
PT-100, a small molecule dipeptidyl peptidase inhibitorg has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism
S Adams et al.
CANCER RESEARCH (2004)
The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides -: In vivo metabolism of pituitary adenylate cyclase-activating polypeptide-(1-38)
L Zhu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance
SL Conarello et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Obesity is associated with macrophage accumulation in adipose tissue
SP Weisberg et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Share Paper
